| Added by | Cavailles |
|---|---|
| Group name | EquipeVC |
| Item Type | Journal Article |
| Title | Cytoplasmic PPAR? is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers |
| Creator | Shao et al. |
| Author | Wanting Shao |
| Author | Christina Kuhn |
| Author | Doris Mayr |
| Author | Nina Ditsch |
| Author | Magdalena Kailuwait |
| Author | Verena Wolf |
| Author | Nadia Harbeck |
| Author | Sven Mahner |
| Author | Udo Jeschke |
| Author | Vincent Cavaillès |
| Author | Sophie Sixou |
| Abstract | BACKGROUND: The aim of this study was to investigate the expression of the nuclear receptor PPAR?, together with that of the cyclooxygenases Cox-1 and Cox-2, in breast cancer (BC) tissues and to correlate the data with several clinicobiological parameters including patient survival. METHODS: In a well characterized cohort of 308 primary BC, PPAR?, Cox-1 and Cox-2 cytoplasmic and nuclear expression were evaluated by immunohistochemistry. Correlations with clinicopathological and aggressiveness features were analyzed, as well as survival using Kaplan-Meier analysis. RESULTS: PPAR? was expressed in almost 58% of the samples with a predominant cytoplasmic location. Cox-1 and Cox-2 were exclusively cytoplasmic. Cytoplasmic PPAR? was inversely correlated with nuclear PPAR? and ER expression, but positively with Cox-1, Cox-2, and other high-risk markers of BC, e.g. HER2, CD133, and N-cadherin. Overall survival analysis demonstrated that cytoplasmic PPAR? had a strong correlation with poor survival in the whole cohort, and even stronger in the subgroup of patients with no Cox-1 expression where cytoplasmic PPAR? expression appeared as an independent marker of poor prognosis. In support of this cross-talk between PPAR? and Cox-1, we found that Cox-1 became a marker of good prognosis only when cytoplasmic PPAR? was expressed at high levels. CONCLUSION: Altogether, these data suggest that the relative expression of cytoplasmic PPAR? and Cox-1 may play an important role in oncogenesis and could be defined as a potential prognosis marker to identify specific high risk BC subgroups. |
| Publication | Journal of Translational Medicine |
| Volume | 18 |
| Issue | 1 |
| Pages | 94 |
| Date | 2020-02-21 |
| Journal Abbr | J Transl Med |
| Language | eng |
| DOI | 10.1186/s12967-020-02271-6 |
| ISSN | 1479-5876 |
| Library Catalog | PubMed |
| Extra | PMID: 32085795 PMCID: PMC7035771 |
| Tags | Biomarkers, Tumor, Breast Neoplasms, clinic, Cox-1, Cox-2, Cytoplasm, Cytoplasmic, Humans, PPAR gamma, PPAR?, Prognosis, Receptor, ErbB-2 |
| Date Added | 2021/09/01 - 17:17:29 |
| Date Modified | 2021/09/01 - 17:28:10 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
